LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
LUYE PHARMA: Interim Report 2024
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
LUYE PHARMA: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 JUNE 2024
LUYE PHARMA: NOTICE OF BOARD MEETING
LUYE PHARMA: DISCLOSEABLE TRANSACTION - THIRD PARTY INVESTMENT IN SHENZHEN LUYE - COMPLETION OF THE INITIAL INVESTMENT
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT -APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FORInnovative Dual TAAR1/5-HT2CR Agonist (LY03020)
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - ERZOFRI (PALIPERIDONE PALMITATE) EXTENDED-RELEASEINJECTABLE SUSPENSION APPROVED BY THE FDA FORTREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
LUYE PHARMA: DISCLOSEABLE TRANSACTIONTHIRD PARTY INVESTMENTIN SHENZHEN LUYE
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - MIMEIXIN (OXYCODONE HYDROCHLORIDE ANDNALOXONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS)APPROVED FOR MARKETING IN CHINA
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATEEXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HASPASSED PAI BY U.S. FDA WITH NO FDA-483
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT -JINYOUPING (ROTIGOTINE MICROSPHERES FOR INJECTION)APPROVED FOR MARKETING IN CHINA
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - MEIBIRUI (PALIPERIDONE PALMITATE INJECTION)APPROVED FOR MARKETING IN CHINA
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - NDA FILED FOR RIVASTIGMINE TWICE WEEKLY TRANSDERMALPATCH IN JAPAN
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
LUYE PHARMA: Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
LUYE PHARMA: Notification Letter and Request Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
LUYE PHARMA: Altered Memorandum of Association and Bye-laws
No Data
No Data